Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
3. InterMune Announces Issuance of U.S. Patent for ITMN-191
4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. InterMune to Release Third Quarter 2008 Financial Results on November 6
10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Washington, USA (PRWEB) September 30, 2014 ... yet efficient arrangements that have evolved in nature over ... biomimetic and bioinspired materials for applications in biophotonics ... Biomedical Optics . The journal is published by SPIE, ... SPIE Digital Library. Several of the peer-reviewed articles are ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 The U.S. ... to Southern Illinois University Edwardsville as part of the ... initiative. The funding is co-administered by the Department of ... Biden, Secretary of Labor Thomas E. Perez and Secretary ... million in job-driven training grants to nearly 270 colleges ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Oct. 9 BioElectronics,Corporation, (Pink Sheets: BIEL), ... has cleared ActiPatch for sale by its,distributor, ... that the experienced sales professionals of,Endotherapeutics will ... team has many decades of experience in ...
... Oct. 8 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... 11,2007, at 1:00 p.m. Pacific Daylight Time. Mike Grey, ... an overview of the,Company,s oncology pipeline. The conference is ... Hotel in San Francisco. A live webcast of ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... Panbio Ltd, an Australian company traded on,the Australian Securities ... all of the issued shares in Panbio for AUD ... issued share capital of,Panbio at approximately AUD 41 million, ...
Cached Biology Technology:Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Inverness Medical Innovations Agrees to Acquire Panbio Ltd. 2
(Date:9/30/2014)... comes to using marijuana, new research, involving mice and ... Journal of Leukocyte Biology , suggests that ... you should. That,s because a team of Italian scientists ... serious long-term damage to the immune system. This damage ... such as multiple sclerosis, inflammatory bowel disease and rheumatoid ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Risky metabolism 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the first time, scientists at Weill Cornell Medical College in ... mechanism that,s crucial to how brain cells communicate. In ... as to how key cellular processes -- called endocytosis and ... in this week,s online edition of Proceedings of the National ...
... appear to have been influenced by RNA polymerase II. ... DNA into messenger-RNA (mRNA), which in turn is the ... is highly conserved through evolution, with many of its ... Single-cell organisms were already in existence 500 million ...
... whose mothers, sisters or daughters test positive for a cancer-causing ... disease but are unaware of that risk. That is ... exploring how families communicate genetic test results. Like their female ... in the BRCA 1 or 2 genes. Male carriers ...
Cached Biology News:Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 2Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 3Evolution with a restricted number of genes 2Men unaware of their cancer risk when female relatives test positive for BRCA mutation 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: